ERBB2 and breast cancer: According to Santisteban et al. (2021), the inclusion of DC vaccines with NAC in HER2-negative BC patients (NCT01431196) is considered a safe approach, as it enhances the pCR rate, especially amongst PD-L1-negative tumors [173].